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Abstract Rationale: Neuromedin-U (NmU) is an agonist
at NMU1R and NMU2R. The brain distribution of NmU
and its receptors, in particular NMU2R, suggests wide-
spread central roles for NmU. In agreement, centrally
administered NmU affects feeding behaviour, energy
expenditure and pituitary output. Further central nervous
system (CNS) roles for NmU warrant investigation.
Objectives: To investigate the CNS role of NmU by
mapping NMU1R and NMU2R mRNA and measuring the
behavioural, endocrine, neurochemical and c-fos response
to intracerebroventricular (i.c.v.) NmU. Methods: Bind-
ing affinity and functional potency of rat NmU was
determined at human NMU1R and NMU2R. Expression
of NMU1R and NMU2R mRNA in rat and human tissue
was determined using semi-quantitative reverse-transcrip-
tion polymerase chain reaction. In in-vivo studies, NmU
was administered i.c.v. to male Sprague-Dawley rats, and
changes in grooming, motor activity and pre-pulse inhi-
bition (PPI) were assessed. In further studies, plasma
endocrine hormones, [DOPAC + HVA]/[dopamine] and
[5-HIAA]/[5-HT] ratios and levels of Fos-like immunore-
activity (FLI) were measured 20 min post-NmU (i.c.v.).
Results: NmU bound to NMU1R (KI, 0.11±0.02 nM) and
NMU2R (KI, 0.21±0.05 nM) with equal affinity and was
equally active at NMU1R (EC50, 1.25±0.05 nM) and
NMU2R (EC50, 1.10±0.20 nM) in a functional assay.
NMU2R mRNA expression was found at the highest
levels in the CNS regions of both rat and human tissues.
NMU1R mRNA expression was restricted to the periphery
of both species with the exception of the rat amygdala.
NmU caused a marked increase in grooming and motor
activity but did not affect PPI. Further, NmU decreased
plasma prolactin but did not affect levels of corticosterone,
luteinising hormone or thyroid stimulating hormone. NmU
elevated levels of 5-HT in the frontal cortex and
hypothalamus, with decreased levels of its metabolites in
the hippocampus and hypothalamus, but did not affect
dopamine function. NmU markedly increased FLI in the
nucleus accumbens, frontal cortex and central amygdala.
Conclusions: These data provide further evidence for
widespread roles for NmU and its receptors in the brain.
Keywords Neuromedin-U (NmU) . NMU2R . NMU1R .
Grooming . Prolactin . 5-HT . Fos . RT-PCR
Introduction
The neuromedins are a family of neuropeptides best
known for their smooth muscle stimulating activity
(Minamino et al. 1985). Neuromedin-U (NmU) was
originally isolated from porcine spinal cord by Minamino
et al. (1985) and was subsequently isolated from a variety
of species including rat (NmU-23), human (NmU-25) and
frog (NmU-25) (Conlon et al. 1988; Domin et al. 1989;
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OHarte et al. 1991). The core active sequence (PheLeu
PheArgProArgAsn-NH2) lies between residues 2 and
8 and is common to mammalian species (Hashimoto et al.
1991; Sakura et al. 1991).
NmU-like immunoreactivity (NmU-ir) is present in the
gastrointestinal and urogenital tracts, and in parts of the
central nervous system (CNS). In rat brain, the highest
levels of NmU-ir are found in the nucleus accumbens,
hypothalamus, anterior pituitary and thalamus (Domin et
al. 1986, 1987). NmU-immunoreactive cell bodies are
confined to the rostrocaudal part of the arcuate nucleus
with a more widespread distribution of immunoreactive
fibres in the nucleus accumbens, medial thalamus and
brain stem, and in the paraventricular (PVN), ventrome-
dial, dorsomedial and arcuate nuclei of the hypothalamus
(Ballesta et al. 1988; Steel et al. 1988). In contrast, in-situ
hybridisation showed discrete localisation of NmU mRNA
in the pituitary pars tuberalis and not in the arcuate nucleus
(Ivanov et al. 2002).
An orphan G-protein coupled receptor (GPCR) termed
NMU1R [previously termed FM-3 (Tan et al. 1998)] was
recently identified as a receptor for NmU (Fujii et al. 2000;
Szekeres et al. 2000; Hedrick et al. 2000; Howard et al.
2000; Kojima et al. 2000). In our own group, NmU-23
was identified as an agonist (EC50, 0.17±0.02 nM) for
NMU1R transiently expressed in HEK 293 cells, by
measuring intracellular calcium mobilisation in response
to a large library of putative GPCR ligands (Szekeres et al.
2000). NMU1R is expressed in a variety of human and rat
peripheral tissues, including lung and small intestine (Fujii
et al. 2000; Szekeres et al. 2000; Howard et al. 2000) but
has not previously been detected in the human or rat brain
(Howard et al. 2000).
A second receptor for NmU, the novel orphan receptor
FM-4 (Howard et al. 2000), was subsequently described
by several groups (Howard et al. 2000; Shan et al. 2000;
Hosoya et al. 2000; Raddatz et al. 2000). In agreement,
each group reported an EC50 of 15 nM for activation of
FM-4 by NmU in functional assays measuring Ca2+
mobilisation. This receptor was termed NMU2R (Howard
et al. 2000). In contrast with NMU1R localisation,
NMU2R expression is mostly restricted to specific regions
of the brain. Using in situ hybridisation, rat NMU2R is
detected in the PVN, the wall of the third ventricle in the
hypothalamus and in the CA1 region of the hippocampus
(Howard et al. 2000). Expression in the periphery is also
reported; for example, Hosoya et al. (2000) found
significant NMU2R expression in the uterus, lung and
ovary. In humans, Raddatz et al. (2000) reported relatively
high levels of NMU2R mRNA in the medulla oblongata,
pontine reticular formation, spinal cord and thalamus.
However, Howard et al. (2000) could detect only weak
human brain expression of NMU2R using Northern
analysis. In the periphery, human NMU2R mRNA is
detected in the kidney, lung (Shan et al. 2000; Raddatz et
al. 2000), trachea, testis (Raddatz et al. 2000) and thyroid
tissue (Shan et al. 2000).
Despite the widespread distribution of NmU and its
receptors, the physiological role of NmU is poorly
understood. Until recently, studies have been hampered
by the lack of known cognate receptor(s). However, it was
found that systemic NmU causes contraction of smooth
muscle, increases arterial blood pressure, modifies intes-
tinal blood flow and ion transport, and increases
adenocorticotrophic hormone (ACTH) and blood cortico-
sterone (Brown and Quito 1988; Sumi et al. 1987;
Gardiner et al. 1990; Malendowicz and Markowska
1994). Consistent with the brain localisation of NmU
and its receptors, NmU also acts centrally to decrease fast-
induced and overnight food intake and gastric acid
secretion (Mondal et al. 2003), with an increase in body
temperature, oxygen consumption and locomotor activity
(Howard et al. 2000; Kojima et al. 2000; Nakazato et al.
2000; Hanada et al. 2001; Ivanov et al. 2002; Wren et al.
2002).
Intracerebroventricular (i.c.v.) injection of NmU in-
creases release of ACTH, AVP and corticosterone,
suggesting a role in regulation of the hypothalamo-
pituitaryadrenal axis (HPA) (Ozaki et al. 2002; Wren et
al. 2002). Consistent with these effects, NmU increases c-
fos expression in the corticotrophin-releasing hormone
(CRH)-containing parvocellular regions of the PVN and
supraoptic nuclei of the hypothalamus (Ozaki et al. 2002;
Ivanov et al. 2002). CRH acts primarily to control ACTH
release from the pituitary gland but has additional effects
in the brain. Central administration of CRH activates
motor activity and grooming behaviour and reduces food
intake (Morley and Levine 1982; Jones et al. 1998). Given
that the central effects of CRH appear similar to those
observed following NmU, and that NmU-induced changes
in feeding behaviour, energy expenditure and motor
activity are absent in the CRH knockout mouse (Hanada
et al. 2001, 2003), it is speculated that the primary role for
NmU is in regulation of the stress response via interaction
with CRH. However, the widespread distribution of NmU
fibres within and outside of the hypothalamus suggests
further central roles for NmU. Indeed, NmU affects the
release of oxytocin (Ozaki et al. 2002) and was recently
found to be pro-nociceptive in both rats and mice (Yu et al.
2003; Cao et al. 2003).
Therefore, the aims of this study were to further
characterise the central effects of NmU on behaviours,
determine effects on various neuroendocrine hormones
and, importantly, to investigate regions of the brain and
neurotransmitters involved in mediating NmU-induced
changes. In order to address discrepancies in previous
reports of receptor distribution, polymerase chain reaction
with reverse transcription (RT-PCR) was used to measure
expression of NMU1R and NMU2R mRNA in rat and
human tissues. Initial behavioural profiling revealed that
central administration of NmU stimulated a prominent
behavioural syndrome characterised by a marked groom-
ing response. Given the stimulant-like effect of NmU on
behaviours, effects on pre-pulse inhibition (PPI) of an
acoustic startle stimulus were determined. Following these
observations, investigation of effects on a range of
neuroendocrine hormones revealed decreased levels of
prolactin. In determining the basis of these changes,
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neurochemical assessment, which determined the effects
of NmU on dopamine (DA) and serotonin (5-hydroxy-
tryptamine; 5-HT) systems, revealed altered 5-HT neuro-
transmission mainly in the frontal cortex and hypothala-
mus. Finally, to investigate anatomical substrates for these
and other effects of NmU, we measured the induction of c-
fos in a range of brain regions to map NmU-induced
neuronal activation.
Materials and methods
Radioligand binding assay
Membrane preparation
HEK293 cells were detached from 150-cm2 flasks with 1 mM
ethylene diamine tetraacetic acid (EDTA) in Ca/Mg-free Dulbeccos
phosphate-buffered saline (DPBS), washed by centrifugation at
300×g and stored as a frozen pellet. The cells were suspended in ice-
cold buffer containing 10 mM TrisHCl (pH 7.4), 5 mM Na-EDTA,
0.1 mM phenylmethylsulphonylfluoride, 1.0 mg/ml bacitracin and
0.1 mg/ml aprotinin (buffer A) and homogenized using a Dounce
homogenizer. The homogenates were centrifuged at 47,000×g for
20 min at 4°C and the membrane pellets were washed twice by
centrifugation in buffer containing 20 mM TrisHCl (pH 7.4), 5 mM
MgCl2, 2 mM Na-ethylene glycol tetraacetic acid (Na-EGTA) and
0.1 mg/ml bacitracin (buffer B). The final pellet was re-suspended in
buffer B (at 2 mg/ml) and stored as aliquots frozen at −70°C. The
protein concentration was measured using the Pierce BCA method
with bovine serum albumin as a standard.
Radioligand binding assay
Membranes (3050 μg/ml of membrane proteins) in buffer B were
incubated with [125I] porcine NmU (120150 pM) in a total volume
of 200 μl for 60 min at 25°C. Non-specific binding, assessed in the
presence of unlabelled porcine NmU-25 (1 μM), represented less
than 1%, with total binding representing 9±0.5% of radioligand in
the incubation. The reaction was terminated by the addition of 3 ml
ice-cold 0.9% NaCl followed by rapid filtration through a Skatron
cell harvester with glass fiber filter mats that had been soaked in
0.3% polyethyleneimine. Filters were counted in a Packard Cobra II
γ counter. All binding assays were done in duplicate, and each
experiment was repeated four to five times. Analyses of all binding
data (KI values) were performed by computer-assisted non-linear
least-square fitting using GRAPHPAD PRISM (Graphpad Software,
Inc., San Diego). Rat NmU was purchased from Bachem Biochem-
icals (King of Prussia, PA). Radiolabelled [125I] porcine NmU-25
(specific activity 2000 Ci/mmol) was a generous gift from New
England Nuclear (Boston, MA).
Calcium mobilisation assays
HEK-293 cells transiently expressing human NMU1R or human
NMU2R were seeded into poly-D-lysine coated 384-well black-wall,
clear-bottom microtitre plates (Becton Dickinson) 24 h prior to
assay. Cells were loaded for 1 h with 1 μM Fluo-4-AM fluorescent
indicator dye (Molecular Probes) in assay buffer (Hanks Balanced
Salts Solution [HBSS], 10 mM HEPES, 200 μM Ca2+, 0.1% BSA,
2.5 mM probenecid), washed three times with assay buffer, then
returned to the incubator for 10 min before assay on a fluorometric
imaging plate reader (FLIPR, Molecular Devices). Maximum
change in fluorescence over baseline was used to determine agonist
response. Concentration response curve data were fitted to a four-
parameter logistic equation using GraFit (Erithacus Software
Limited).
Quantitative RT-PCR analysis
For TaqMan RT-PCR mRNA localisation studies in rats, Sprague-
Dawley rats (300350 g) were killed by CO2 asphyxia followed by
cervical dislocation. Tissues were dissected free, and the brain was
further sub-divided into 15 regions. Each tissue was pooled from 6
16 rats, depending on the size of the individual tissue samples
obtained. Human tissue or non-pooled RNA was purchased from
Biochain (San Leandro, CA, USA), Invitrogen (Leek, The Nether-
lands), Clontech (Palo Alto, CA, USA) or donated from the
Netherlands Brain Bank (Amsterdam).
Total RNA was extracted from the tissue using TRIzol reagent
(Life Technologies), according to the manufacturers suggested
protocol, with the addition of an extra chloroform extraction step
and phase separation, and an extra wash of the isolated RNA in 70%
ethanol. The RNA was re-suspended in autoclaved, ultra pure water
and the concentration calculated by A260 measurement. RNA quality
was assessed by electrophoresis on a 1% agarose gel. For human
samples, poly A + RNAwas further purified from total RNA by the
PolyATract method according to manufacturers instructions
(Promega, USA) and RNA was re-suspended and its concentration
quantified as described above.
First-strand cDNA synthesis was carried out by oligo(dT) priming
of 1 μg of each total RNA sample or by random priming of each
1 μg polyA + RNA sample [0.01 M DTT, 0.5 mM each dNTP,
0.5 μg oligo(dT) primer or 0.15 μg random 9-mer, 40 U
RNAseOUT ribonuclease inhibitor (Life Technologies) 200 U
Superscript II reverse transcriptase (Life Technologies)]. For rat
samples, triplicate RT reactions were performed along with an
additional reaction in which the reverse transcriptase was omitted to
allow for assessment of genomic DNA contamination of the RNA.
For human samples, RNA samples from four non-diseased
individuals (two males, two females) per tissue were treated
separately as above. The resulting cDNA products were divided
into 20 aliquots (rat samples) or 1000 aliquots (human samples) for
parallel TaqMan PCR reactions using different primer and probe sets
for quantification of multiple cDNA sequences.
Quantitative RT-PCR was carried out using an ABI 7700
sequence detector (Perkin Elmer) on the cDNA samples [2.5 mM
MgCl2, 0.2 mM dATP, dCTP, dGTP and dUTP, 0.1 μM each primer,
0.05 μM Taqman probe, 0.01 U AmpErase uracil-N-glycosylase
(Perkin Elmer), 0.0125 U Amplitaq Gold DNA polymerase (Perkin
Elmer); 50°C for 2 min, 95°C for 10 min followed by 40 cycles of
95°C for 15 s, 60°C for 1 min]. Additional reactions were performed
on each 96-well plate using known dilutions of either rat or human
genomic DNA as a PCR template to allow construction of a standard
curve relating threshold cycle to template copy number.
TaqMan primer and probe sets for rat and human NMU1R and
NMU2R and for the housekeeping gene β-actin were designed from
sequences in the Genbank database using Primer Express V1.0
software (Perkin Elmer). Levels of mRNA measured were
calculated as copies of mRNA detected per nanogram total RNA
(rat) or per nanogram polyA + RNA (human).
The primer and probe sequences (forward primer, reverse primer
and TaqMan probe)are shown here for rat and human.
 Rat
 NMU1R
 Forward primer: CTGCCCATGGTCACCATCA
 Reverse primer: AACATCCTCTCCCTCCGCA
 TaqMan probe: TCAGCCCAATGAGCAGGTACAG-
CACA
 NMU2R
 Forward primer: TGCTGTTTGTCTTGGTCCTCG
 Reverse primer: AAAGCTGAAGAAGAGCCGGTC
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 TaqMan probe: TTTGCCATCTGCTGGACCCCCTTC
 β-Actin:
 Forward primer: TCTGTGTGGATTGGTGGCTCTA
 Reverse primer: CTGCTTGCTG ATCCACATCTG
 TaqMan probe: CCTGGCCTCACTGTCCACCTTCC
 Human
 NMUR1
 Forward primer: GGCTCCAGCAGCACGATC
 Reverse primer: GCAGATGCCGAAAGCACGCACG
 TaqMan probe: ACAGCATCTTGGTCACTTGTCTC-
CGGC
 NMUR2
 Forward primer: TGACCGAAGATATAGGTCCCCA
 Reverse primer: TGTTCACTAGAGAGGGCTGCTG
 TaqMan probe: TCCCATGTCAGTCATCCATGCA-
CAACTCT
 β-Actin:
 Forward primer: GAGCTACGAGCTGCCTGACG
 Reverse primer: GTAGTTTCGTGGATGCCACAG-
GACT
 Taqman probe: CATCACCATTGGCAATGAGCG-
GTTCC
In vivo studies
All in vivo studies were conducted in accordance with the United
Kingdom Animals (Scientific Procedures) Act, 1986, and con-
formed to GlaxoSmithKline ethics standards.
Rat NmU was administered by i.c.v. injection in all studies.
Sprague-Dawley rats (Charles River, 250300 g at the time of
surgery) were implanted under anaesthesiaDomitor (medetomi-
dine HCl, 0.4 mg/kg s.c., Pfizer, Sandwich, UK); Sublimaze
(fentanyl, 0.45 mg/kg i.p., Janssen-Cilag, High Wycombe, UK)
with an indwelling cannula directed towards either the left or right
lateral ventricle (co-ordinates: ±1.6 mm from midline, 0.8 mm
caudal from bregma, −4.1 mm from skull surface, with incisor bar at
−3.2 mm below zero, according to Paxinos and Watson 1986).
Anaesthesia was reversed by Antisedan (atipamezole HCl, 2.5 mg/
kg s.c., Pfizer, Kent, UK) and post-operative analgesia provided by
Nubain (nalbuphine HCl, 2 mg/kg s.c., Du Pont Pharmaceuticals,
Letchworth Garden City, UK). Following 7 days post-operative
recovery, correct cannula placement was verified by an intense
drinking response to angiotensin II (100 ng i.c.v.; Simpson et al.
1978). At least 7 days elapsed before further drug testing. Rats were
used in up to four separate experiments with a minimum of 7 days
between each drug administration. Rats were housed singly, in a
temperature-controlled environment (20±1°C), under a 12-h/12-h
light/dark cycle (lights on at 0700 hours). Food and water were
available ad libitum. Rats were housed in the experimental room,
and all testing was conducted between 0800 hours and 1800 hours.
Treatment groups were balanced for previous treatment and time of
day.
Behaviour in a familiar environment
The choice of behavioural studies was based on initial pilot studies
(unpublished data), in which NmU caused general arousal. There-
fore, behavioural changes were measured in a familiar environment
to minimise baseline activity. Following ≥60-min habituation to
clear Perspex observation cages (42 [L]×21 [W] ×20 [H] cm), rats
were administered NmU (3 μg or 10 μg) or vehicle and immediately
returned to the cages. Rats were videotaped for 60 min and
behaviours [grooming (body grooming, face washing and scratch-
ing), rearing and quiet (rats generally immobile and curled up)] were
scored, in 15-min time bins, as both total duration(s) and number of
bouts. Motor activity was scored as transits across the length of the
cage. The observer was blind to treatment.
Motor activity in a familiar environment
Motor activity was measured using observation cages placed within
a frame equipped with a series of infra-red beams along its length (5)
and width (3) (AM1052 Activity Monitor, Benwick Electronics,
Essex, UK). Following ≧60-min habituation to observation cages
and the recording frame, rats were administered NmU (0.03, 0.3 or
3 μg) or vehicle and immediately returned to the recording cages.
Motor activity was recorded as total activity (total beam breaks) and
total transits (total ambulations across the length of the cage) in 5-
min time bins for 120 min.
Pre-pulse inhibition of an acoustic startle response
Eight computer-controlled startle chambers housed in sound-
attenuated boxes were used for these studies (IDT, GlaxoSmithK-
line, Harlow). The startle chamber was constructed from clear
Perspex (19 [L]×16 [W]×23 [H] cm] and was equipped with a
sprung metal grid floor, a loudspeaker capable of delivering a 120-
dB tone and a light on the back wall of the chamber. The magnitude
of deflection of the grid floor, caused by the startle response of the
rat, was recorded by an accelerometer attached to the sprung
platform. The apparatus was controlled by custom-written software
(IDT, GlaxoSmithKline) run using a PC. Testing used a pulse
amplitude of 110 dB white noise for 50 ms, and the pre-pulse
amplitude was 80 dB white noise for 10 ms. Rats received five trials
of pulse alone and five trials of a pre-pulse followed 60 ms (Inter
Stimulus Interval, ISI) later by a pulse. Each of the trial types were
paired in random order with an inter-trial delay of 15 s. Background
noise was 70 dB white noise. The data for the first pair of trials was
discarded and a mean within animal figure obtained from the other
four pairs of trials. Rats were habituated to the PPI procedure on
four separate occasions. The animals were assigned to treatment
groups based on the level of PPI and startle amplitude on the last
habituation test, and balanced across startle chambers. Doses were
chosen in a range that would not markedly affect motor activity
(based on previous motor activity studies). On the test day, NmU
(0.1, 0.3 or 1 μg i.c.v.) or vehicle was administered immediately
prior to placing animals into the startle chamber and testing started
15 min later. PPI was calculated as:
PPI ¼
100
startle amplitude for pre pulseþ
pulse=startle amplitude for pulse alone
  
 100:
Neurochemistry and neuroendocrine hormones
Previously untreated rats were administered with NmU (0.03, 0.3
and 3 μg) or vehicle and, 20 min later, were killed by rapid
decapitation. The dose range and sampling times were based on
peak motor activity and grooming times from behavioural studies.
Neuroendocrine hormones
Trunk blood was collected into pre-chilled tubes containing EDTA
and centrifuged at 1750 g (4°C) for 15 min to harvest plasma which
was then stored at −70°C for radioimmunoassay of prolactin, thyroid
stimulating hormone (TSH), luteinising hormone (LH) (Amersham
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Life Science Ltd, UK) and corticosterone (Immunodiagnostic
Systems Limited, UK).
Neurochemistry
Sample preparation Brains were removed, frozen and stored at
−80°C until assay. Tissue samples were dissected from the dorsal
striatum, nucleus accumbens, hippocampus, hypothalamus and
frontal cortex (both left and right hemispheres) and snap frozen in
1.5 ml Eppendorf sample tubes on cardice. The frozen samples were
then transferred into a pre-weighed 1.5-ml Eppendorf sample tube.
A volume of 10 μl homogenising buffer (0.1% w/v Na
Metabisulphite, 0.01% w/v EDTA, 0.1% w/v L-cysteine, 0.4 M
perchloric acid) per milligram of tissue was then added to each
sample region and homogenised using an electric homogeniser
(Ultra Turrax T25, Janke and Kunkel, Germany). A volume of the
resultant slurry was put into a 1.5-ml Eppendorf and spun on a
centrifuge (Labofuge 400R, Heraeus Instruments, Germany) at
9500 g, 4°C for 10 min. After centrifugation, 20 μl of the clear
supernatant layers were put into a limited volume glass vial (0.2 ml
borate silica vials, Chromacol, UK). Vials were then placed into a
cooled autosampler tray (832 Temperature regulator, Gilson, France)
at 4°C and run on the high-performance liquid chromatography
(HPLC) system.
Chromatographic conditions A solvent delivery pump (PU-980,
Jasco, Japan) was used in conjunction with an electrochemical
amperometric detector (Decade, Antec-Leyden, Netherlands) fitted
with a 3-mm glassy carbon electrode with a working electrode set at
+800 mV versus Ag/AgCl (VT-03, Antec-Leyden, Netherlands).
The signal was then passed through a low-pass in-line noise killer
(Antec-Leyden, Netherlands) set at 26-s peak width before the data
was captured using Waters Millennium32. An autosampler (234
Autosampler, Gilson, France) fitted with a six port rotary valve
(Model 7125, Rheodyne, Berkley, CA, USA) with a 20-μl injection
loop was used for a 5 μl central loop fill injection of brain tissue
samples. Chromatographic separations were performed using a
Waters Symmetry (C18 3.5 μm, 4.6×75 mm) column fitted with a
20-mm C18 Waters Sentry guard column. The mobile phase
consisted of 0.07 M KH2PO4 (Fisher, UK, HPLC for Electrochem-
ical Detection Grade), 1 mM octane sulphonic acid (Fisher, UK,
HPLC for Electrochemical Detection Grade) and 0.1 mM Na2
EDTA (Fisher, UK, 0.1 M solution, HPLC for Electrochemical
Detection Grade) made up in 10% MeOH (Methanol 205, Super
Purity, Romil, Cambridge, UK), 0.5% propan-2-ol (Super Purity,
Romil, Cambridge, UK); the pH was adjusted to 2.85 with
orthophosphoric acid (85%, Fisher, UK HPLC grade). The mobile
phase was then filtered through a 0.22-μm filter (Millipore, Bedford,
MA, USA), degassed on line (DEG-103, Kontron, Japan) and
delivered at a rate of 1.50 ml/min at a temperature of 30°C. Samples
were compared against a calibration curve generated by a mixed
standard of 1, 3, 10, 30, 50 and 100 ng/ml of 3,4-dihydroxyphe-
nylacetic acid (DOPAC), dopamine HCl (DA), 5-hydroxyindole-3-
acetic acid (5-HIAA), homovanillic acid (HVA), 3-methoxytyramine
HCL (3-MT), and 5-hydroxytryptamine creatine sulphate (5-HT)
(all components from Sigma, St. Louis, USA). Components in the
samples were then identified by retention time and quantified using
the calibration curve with a final adjustment for the dilution by
homogenising buffer and taking into account the presence of either
hydrochloride or the creatine sulphate complex. The levels of
substrates in each brain sample were expressed as nanogram per
milligram of tissue. Turnover rates were assessed by calculating the
following ratios: DOPAC/DA, HVA/DA, and 5-HIAA/5-HT.
Fos-like immunohistochemistry
Rats previously used in another behavioural study (response to i.c.v.
orexin-B) were allowed 21 days recovery with regular handling, and
treatment groups were randomised according to previous injection.
Rats were injected with vehicle or NmU (10 μg i.c.v.) and returned
to their home cage. Two hours post-injection, animals were
anaesthetised with sodium pentobarbitone (200 mg kg−1, i.p.) and
intracardially perfused with heparinised saline followed by 4% (w/v)
paraformaldehyde (PFA, 200 ml) in 0.1 M phosphate buffer. Fos
immunohistochemistry was carried out according to the methods of
Leslie et al. (1993). In summary, brains were removed and post-
fixed for 2 days in 4% PFA (4°C). Coronal sections (50 μm) were
cut on a cryostat and each brain section individually placed into
immunobuffer (120 mM NaCl, 5 mM KCl, 9 mM Na2HPO4, 15 mM
NaH2PO4, 1 mM merthiolate containing 0.3% [v/v] Triton X-100).
Endogenous peroxidase activity was removed with hydrogen
peroxide (H2O2, 30 min, 0.03% [v/v] in immunobuffer) prior to
sequential incubation in 2% (v/v) rabbit serum in immunobuffer
(blocking buffer, 24 h), followed by affinity-purified polyclonal
sheep antiserum raised to the c-fos protein (1:2000 in blocking
buffer, 60 h; Genosys Biochemicals, UK, Cat. No. OA-11-824), and
then biotinylated secondary rabbit anti-sheep antibody (1:200 in
blocking buffer, 24 h). Sections were incubated in avidin/biotin/
horseradish peroxidase conjugate (3 h), followed by incubation in 3,
3 diaminobenzidine (DAB, 0.3% [w/v], 10 min in 0.1 M phosphate
buffer [pH 7.4]). To reveal sites of Fos-like immunoreactivity (FLI;
blackbrown nuclear staining), H2O2 [20 μl, 0.1% (v/v)] solution
was added to the DAB solution and washed off with TrisHCl
(50 mM, pH 7.4) once sections had turned a beigebrown colour.
All sections were further washed (×2) in TrisHCl to ensure the
removal of all DAB solution, mounted onto glass microscope slides
and allowed to dry overnight. In order to observe FLI under a light
microscope, sections were dehydrated in absolute alcohol and
cleared using Citroclear (xylene substitute), and cover-slipped with
DPX mounting medium. Sections were examined by bright-field
microscopy and cells that exhibited FLI in pre-selected brain regions
(nucleus accumbens, frontal cortex, paraventricular thalamus, hip-
pocampus, central amygdala and paraventricular hypothalamus)
were counted by an independent observer blind to treatment group.
Nuclei were counted in a 400×400-μm box. Where the box extended
beyond the chosen anatomical region, counting was limited to the
boundary of that region.
Preparation and administration of Neuromedin-U
Rat NmU was purchased as an acetate salt from Bachem (UK) Ltd.
The peptide was dissolved in sterile 0.9% saline solution and doses
were corrected for salt content. The pH of the peptide solution was
adjusted to approximately 7, using 0.5 M NaOH solution. Aliquots
of the highest concentration of 10 μg (3.8 nmol) were snap frozen at
−80°C prior to storage at −20°C. On experimental days, individual
aliquots were stored on ice and discarded at the end of each day. In
all studies, NmU or vehicle were injected i.c.v. in a volume of 5 μl
over 60 s at a constant rate. The injection needle (extending 1 mm
from the end of the guide cannula) was left in place for a further 90 s
to allow for complete diffusion of the peptide.
Data analysis
Data for observed behaviours were analysed using KruskallWallis
one-way analysis of variance (ANOVA) by ranks followed by
MannWhitney U-tests where appropriate. Total motor activity, %
PPI, startle amplitude and endocrine hormones were analysed using
one-way ANOVA followed by Dunnetts t-test post-hoc analysis.
Data for activity×time and transits×time were analysed using two-
way ANOVA followed by least significant difference post-hoc
analysis at individual time points. Data were transformed to correct
for heterogeneity of variance when appropriate. Data for steady-state
levels of transmitters were analysed using a 4×5×6 ANOVA with a
main factor of dose (0, 0.03, 0.3, 3 μg), and repeated-measurements
factors of brain region (dorsal striatum, nucleus accumbens,
hippocampus, hypothalamus and frontal cortex) and neurochemical
index (DA, DOPAC, HVA, 3-MT, 5-HT, 5-HIAA). Turnover rates
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were analysed using a 4×5×4 ANOVAwith a main factor of dose (0,
0.03, 0.3, 3 μg), and repeated-measurements factors of brain region
(dorsal striatum, nucleus accumbens, hippocampus, hypothalamus
and frontal cortex) and turnover ratio (DOPAC/DA, HVA/DA,
DOPAC/HVA, 5-HIAA/5-HT). Differences between individual
means were analysed using the post-hoc Fishers Protected test.
For immunohistochemistry studies, counts for numbers of immu-
noreactive nuclei in each region were assessed using one-way
ANOVA followed by Duncans New Multiple Range post-hoc
analysis. All statistical analyses used Statistica (Statsoft, Ca, USA).
In all cases P<0.05 was taken as the level of significance.
Results
Binding affinity and functional potency of NmU at
NMU1R and NMU2R
We studied the binding affinity and functional potency of
rat NmU at both human NMU1R and human NMU2R
when transiently expressed in HEK293 cells. NmU was
able to displace [125I]-pNmU25 with equal potency from
both NMU1R [KI=0.11±0.02 nM (n=4)] and NMU2R
[KI=0.21±0.05 nM (n=5)] (Fig. 1). In functional calcium
mobilization assays performed on a FLIPR, NmU was a
full agonist at both NMU1R and NMU2R with mean EC50
values of 1.25±0.05 nM for NMU1R and 1.10±0.20 nM
for NMU2R (n=4) (Fig. 2). Thus, NmU is equally active at
both NMU1R and NMU2R.
Quantitative RT-PCR analysis
Expression of NMUR1 and NMUR2 mRNA in human
tissues is shown in Fig. 3a. NMU1R mRNAwas expressed
at low levels in all CNS tissues assessed. In peripheral
tissues, expression was highest in adipose tissue and
moderate in lung, intestine, spleen and lymphocytes.
NMU2R mRNA was found in all brain CNS tissues
assessed with highest levels in the hypothalamus, medulla
oblongata, substantia nigra and thalamus. In periphery,
relatively low expression of NMU2R mRNAwas detected
in the heart, lung, kidney and stomach.
Expression of NMU1R and NMU2R mRNA in rat
tissues is shown in Fig. 3b. NMU1R mRNA could not be
detected in any CNS areas assessed, with the exception of
very low levels of expression in the amygdala. In
peripheral tissues, expression of NMU1R was found in
lung, small intestine, stomach and testis, with the highest
levels detected in the spleen. NMU2R mRNA expression
was detected at highest levels in CNS tissues, with the
highest expression in the medulla oblongata. Moderate
levels of expression were found in the hypothalamus,
spinal cord, striatum and whole brain tissue. Low levels of
expression were found in all other CNS tissues, including
all cortical areas; however, no expression was detected in
the hippocampus. In peripheral tissues, highest levels of
NMU2R receptor expression were detected in the ovary
with lower levels of expression also found in the lung,
stomach and testis.
Behaviour in a familiar environment
Centrally administered NmU induced a behavioural syn-
drome characterised by an intense grooming response.
NmU increased the time spent face washing [H(2, N=18)
=8.67, P<0.05; Fig. 4a], time spent scratching [H(2, N=18)
Fig. 1 Competition binding curves for rat neuromedin-U (NmU)
against [125I] porcine NmU-25 binding to membranes isolated from
HEK293 cells transiently transfected with human NMU1R (filled
square) and NMU2R (filled triangle). Data are means of duplicate
determinations from one representative experiment. Mean KI values
were 0.11±0.02 nM (n=4) and 0.21±0.05 nM (n=5) for NMU1R and
NMU2R, respectively
Fig. 2 Concentration-dependent stimulation of Ca2+ mobilization
by rat neuromedin-U (NmU) in HEK293 cells transiently expressing
NMU1R or NMU2R. Data is expressed as a percentage of the
maximal response seen for each receptor. Mean EC50 values were
1.25±0.05 nM for NMU1R and 1.10±0.20 nM for NMU2R (n=4)
"Fig. 3 TaqMan quantitative reverse-transcription polymerase chain
reaction (RT-PCR) analysis of NMU1R and NMU2R mRNA levels.
In human tissues (a) the cDNA from the reverse transcription of
1 ng poly A + RNA from multiple tissues for four different non-
diseased individuals was assessed for its NMUR and housekeeper
genes (β-actin shown for reference) using TaqMan PCR. Data are
presented as the mean (±SEM) of four individuals mRNA levels for
each tissue. (Intestine is an equal pool of one individuals small and
another individuals large intestine). In rat tissues (b) data is for
copies of mRNA per nanogram total RNA. Data are presented as
mean (±SEM) of four independent RT-PCRs using total RNA
pooled from 616 rats
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=11.84, P<0.05; Fig. 4b] and time spent body grooming
[H(2, N=18)=8.47, P<0.05; Fig. 4c], at 3 μg and 10 μg
(P<0.05). The reduction in time spent quiet was
pronounced [H(2, N=18)=10.75, P<0.05; Fig. 4d] at
3 μg and 10 μg (P<0.05). Time spent rearing was not
affected (data not shown). NmU also increased bouts of
face washing [H(2, N=18)=9.6, P<0.05], bouts of
scratching [H(2, N=18)=12.45, P<0.01] and bouts of
body grooming [H(2, N=18)=8.67, P<0.05] at 3 μg and
10 μg (P<0.05) (bouts data not shown). Bouts of rearing
and quiet behaviour were not affected (data not shown).
NmU did not affect total number of cage transits (data not
shown).
Motor activity in a familiar environment
NmU-stimulated motor activity (Fig. 5). Total activity was
increased (F3,41=10.06, P<0.05, Fig. 5a) at 0.3 μg and
3 μg (P<0.05). NmU did not affect total transits
(ambulations across the length of the cage) (Fig. 5c,d),
suggesting that the observed increase in total activity does
not represent horizontal locomotor activity. The stimula-
tory effects of NmU on activity changed significantly over
the 120-min recording period (F33,451=4.49, P<0.05,
Fig. 5b) with a return to baseline levels of activity after
110 min. At 0.3 μg, activity was elevated above vehicle
levels between 20 min and 70 min post-injection. At the
highest dose (3 μg), activity was elevated significantly for
between 10 min and 100 min post-injection (P<0.05 at
each time interval).
Pre-pulse inhibition of an acoustic startle response
NmU did not affect PPI (for example, vehicle=59.6±5.4;
1 μg=55.6±6.5% PPI, data not shown) or startle amplitude
(for example, vehicle=1788±225; 1 μg=1973±297 arbi-
trary units, data not shown).
Neurochemistry and neuroendocrine markers
Neuroendocrine hormones
NmU caused a dose-related reduction in plasma prolactin
levels, which was significant at 3 μg (P<0.05; Fig. 6).
Fig. 4a–d Effects of neuromedin-U (NmU) on observed behaviour
(n=6). Behaviours were scored in 15-min time bins for 60 min post-
dose. For individual behaviours, total time spent is shown in the left
panel and time spent during each 15-min time bin is shown in the
right panel. a Data for time spent face washing (s), b time spent
scratching (s), c time spent body grooming (s) and d time spent quiet
(s) are shown as the means (±SEM). Significant differences from
vehicle are shown by *P<0.05
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Fig. 5a–d Effects of neuromedin-U (NmU) on motor activity in a
familiar environment (n=1012). Motor activity was recorded in 5-
min time bins for 120 min post-dose. Data for total activity (a) and
total transits (c), and for total activity (b) and total transits (d) over
time are shown as the means (±SEM). Significant differences from
vehicle are shown by *P<0.05
Table 1 Effects of neuromedin-
U (NmU) on serotonin (5-HT)
neurotransmission in rat brain
extracts. Data are expressed as
means (±SEM). Significant dif-
ferences from vehicle are shown
by *P<0.05
Brain region NmU (μg i.c.v.) [5-HT] [5-HIAA]/[5-HT]
Frontal cortex Vehicle 410.42±15.76 0.496±0.023
0.03 428.37±09.00 0.405±0.021
0.3 411.97±23.02 0.431±0.028
3 471.94±18.40* 0.481±0.047
Hippocampus Vehicle 263.76±16.48 1.007±0.064
0.03 270.03±11.78 0.907±0.072
0.3 247.77±11.09 0.810±0.048*
3 293.88±24.21 0.824±0.036
Hypothalamus Vehicle 505.61±22.33 0.523±0.025
0.03 566.03±11.10 0.489±0.021
0.3 598.83±19.42* 0.463±0.021
3 571.36±27.35* 0.446±0.016*
Nucleus accumbens Vehicle 466.26±26.56 0.733±0.045
0.03 463.89±33.59 0.743±0.061
0.3 406.05±28.34 0.752±0.028
3 456.16±26.47 0.732±0.030
Striatum Vehicle 273.93±17.91 1.180±0.112
0.03 270.78±08.62 1.103±0.044
0.3 269.88±13.76 1.117±0.061
3 307.47±19.41 1.065±0.230
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Plasma levels of corticosterone, LH or TSH were not
affected.
Neurochemistry
NmU significantly affected 5-HT neurotransmission in the
frontal cortex and hypothalamus (Table 1). In the frontal
cortex, the overall ANOVA revealed a main effect of dose
(F3,24=3.4; P<0.05) and a significant neurochemical
index×dose interaction (F12,96=1.8; P=0.05). The post-
hoc Fishers test confirmed that NmU (3 μg) produced a
significant increase in steady-state levels of 5-HT
(P<0.05). In the hypothalamus, ANOVA yielded a signif-
icant neurochemical index×dose interaction (F12,96=1.9;
P<0.05). NmU (0.3 μg and 3 μg) were shown to increase
levels of 5-HT significantly (P<0.01 and P<0.05,
respectively). NmU (3 μg) also decreased significantly
the turnover of 5-HT, as expressed by the 5-HIAA/5-HT
ratio (P<0.05). NmU did not affect levels of DA or the
ratio of DA to its metabolites in any brain region tested
(data not shown).
Fos-like immunohistochemistry
NmU (10 μg) markedly increased the number of Fos-like
immunoreactive cell bodies in the nucleus accumbens,
frontal cortex and central amygdala compared with vehicle
(P<0.05; Figs 7, 8). NmU did not alter levels of FLI in the
paraventricular thalamus, hippocampus or paraventricular
hypothalamus.
Discussion
In agreement with previous data (Raddatz et al. 2000;
Howard et al. 2000), the results of in vitro functional and
Fig. 6a–d Effects of neurome-
din-U (NmU) on plasma endo-
crine hormones. Trunk blood
samples were collected 20 min
post-dose for radioimmunoas-
say. Levels of corticosterone
(ng/ml) (a), LH (ng/ml) (b),
prolactin (ng/ml) (c) and TSH
(ng/ml) (d) are shown as the
means (±SEM). Significant dif-
ferences from vehicle are shown
by *P<0.05
Fig. 7 Numbers of Fos-like immunoreactive nuclei were deter-
mined in brains perfused 2 h after i.c.v. administration of vehicle or
neuromedin-U (NmU; 10 μg). Fos-like immunoreactivity (FLI) was
counted in a 400×400-μm grid (by an observer blind to treatment
group) in the nucleus accumbens (Acb), frontal cortex (Fc),
paraventricular thalamus (PVT), hippocampus (HIP), central amyg-
dala (CeA) and paraventricular hypothalamus (HYP). Significant
increases in FLI were evident in the Acb, Fc and CeA. *P<0.05 after
significant one-way ANOVA, n=3 per group
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binding assays showed that rat NmU is a potent agonist at
both NMU1R and NMU2R. Given the CNS localisation of
these subtypes, these data confirm that the in vivo effects
of NmU described here could be mediated by either of
these receptors. Here, we provide the first concurrent
description of NMU1R and NMU2R in both rat and
human tissues, extend the description of behavioural
activation following NmU and provide the first description
of NmU affecting 5-HT neurochemistry and plasma
prolactin levels. Further, we showed discrete FLI in the
frontal cortex, nucleus accumbens and central amygdala.
To address discrepancies in previous reports of NMU1R
and NMU2R distribution, RT-PCR was used to measure
NMU1R and NMU2R mRNA in rat and human tissues.
Expression of a housekeeping gene, β-actin, was used to
control for discrepancies in RNA quality between tissue
samples. In both rats and humans, NMU1R mRNA was
detected in peripheral tissues, with highest expression in
the gastrointestinal tract including the stomach, intestine
and spleen. In agreement with Raddatz et al. (2000), very
low levels of NMU1R mRNA were detected in human
brain. With the exception of the amygdala, NMU1R
mRNA was undetectable in rat brain. However, NMU1R
mRNAwas expressed in the rat amygdala, implying that a
role for NMU1R in the brain cannot be ruled out. This
description of NMU1R in the rat brain contrasts with Fujii
et al. (2000) and Howard et al. (2000), who could find no
evidence of NMU1R mRNA expression in any brain
region tested, using in situ hybridisation. Such discrepan-
cies may partly be explained by differences in the
methodologies and sensitivities of the detection system.
Overall, the distribution of NMU1R reported here is in
broad agreement with previous reports of NMU1R
distribution in humans (Raddatz et al. 2000; Hedrick et
al. 2000; Howard et al. 2000) and rats (Howard et al. 2000;
Fujii et al. 2000), and is consistent with roles for NMU1R
and NMU2R in peripheral smooth muscle contraction and
in gastrointestinal function (Szekeres et al. 2000). Future
studies will use selective radiolabelled ligands, or
antibodies to the receptor, to map the localisation of
receptor protein.
Expression of NMU2R mRNA was relatively high in
the CNS of rats and humans. Whilst these data are in
general agreement with other recent reports of NMU2R
mRNA distribution shown using RT-PCR (Hosoya et al.
2000; Raddatz et al. 2000), Northern analysis (Howard et
al. 2000; Shan et al. 2000) and in situ hybridisation
(Howard et al. 2000), here we show a more diverse brain
expression of NMU2R mRNA. There were higher CNS
levels of expression of NMU2R in all 18 human regions
tested. Expression in rats was relatively high in the
medulla oblongata, pons, spinal cord, striatum, substantia
nigra and whole brain tissue. The presence of NMU2R
mRNA in the nucleus accumbens, striatum and substantia
nigra has not been previously described. Higher levels of
NMU2R mRNA were found in the hypothalamus of both
species, confirming previous reports by Raddatz et al.
(2000) and Hosoya et al. (2000) and, importantly, Howard
et al. (2000) who showed mRNA expression specifically
in the hypothalamic paraventricular nucleus (PVN) and in
the lining of the third ventricle of the hypothalamus. The
reported effects of centrally administered NmU on food
intake, energy expenditure and stress regulation (Howard
et al. 2000; Nakazato et al. 2000; Wren et al. 2002) are
Fig. 8 Photomicrograph of in-
dicative Fos-like immunoreac-
tivity (FLI) in the central
amygdala (CeA) of a neurome-
din-U (NmU; 10 μg i.c.v.)-
treated (A) or vehicle-treated
(B) rat, and in the frontal cortex
(Fc) of a NmU- (10 μg i.c.v.)
(C) or vehicle- (D) -treated rat.
Intense FLI (arrow) was evident
only in the brains of animals
administered NmU. Bar 200 μm
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consistent with the hypothalamic localisation of both
NMU2R and NmU. However, the overall brain distribu-
tion of NMU2R and, to a lesser extent, NMU1R suggests
that the central functions of NmU and its receptors are
more widespread. To reveal further central roles for NmU,
we characterised the response to i.c.v.-administered NmU
by measuring various behavioural, neurochemical and
neuroendocrine end points.
A detailed examination of the behavioural outcomes
following NmU (up to 10 μg) revealed that NmU caused
an intense behavioural syndrome in rats. As previously
reported (Kojima et al. 2000; Hanada et al. 2001; Wren et
al. 2002), NmU (310 μg) caused a marked increase in
grooming and grooming-related behaviours (face washing
and scratching), and reduced time spent quiet. NmU (up to
3 μg) also increased motor activity in a familiar environ-
ment in a dose-dependent manner. In agreement with
Nakazato et al. (2000), the motor activation was prolonged
with elevation in levels of activity for up to 100 min. This
contrasts with findings by Howard et al. (2000) who
reported a transient increase in motor activity following
i.c.v.-administered NmU. In the present study, motor
activity was measured in two ways, such that horizontal
locomotor activity (i.e. full transits across the cage) was
separated from generalised motor activation (i.e. total
beam breaks). NmU did not affect cage transits, suggesting
that the NmU-induced increase in motor activity reported
here and that in the literature (Nakazato et al. 2000;
Hanada et al. 2001; Wren et al. 2002) do not represent
directional movement but may result from induction of
behaviours such as grooming.
Intense grooming behaviour in rats is characteristic of
the stress response (Dunn et al. 1981) and is activated by
CRH (Jones et al. 1998). Given the discrete localisation of
NMU2R in the PVN, a major output centre of CRH, it is
speculated that NmU activates grooming via CRH release
from the PVN. In agreement, Hanada et al. (2001) showed
a reduction in NmU-induced grooming and locomotor
activity following anti-CRH IgG and α-hCRH, and an
absence of NmU-induced locomotor activity in the CRH
knockout (KO) mouse. Further, Wren et al. (2002),
showed NmU-induced grooming after direct injection to
the PVN. However, it should be considered that NmU may
affect CRH, or other output systems, outside of the
hypothalamus to cause its marked behavioural effects.
Alternative sites of action of NmU are suggested in this
discussion.
The widespread localisation of NmU fibres in hypotha-
lamic nuclei make it ideally positioned to affect multiple
hypothalamic output systems. In this study, we evaluated a
snap shot of NmU-induced neuroendocrine changes at a
single time point (20 min post-dose). Doses of NmU were
equivalent to those used in behavioural studies. Centrally
administered NmU increases plasma ACTH, corticoste-
rone, arginine vasopressin and oxytocin (Ozaki et al. 2002;
Wren et al. 2002). Here we extended these findings by
showing a dose-related reduction in plasma prolactin
following NmU (0.33 μg). Similar reductions in plasma
prolactin levels are seen following i.c.v.-administered
orexin-A (Hagan et al. 1999; Jones et al. 2001) and
suggest that these neuropeptides may be involved in the
inhibitory control of prolactin. One candidate for this role
is DA, which when released from DA neurons in the
tuberoinfundibular pathway potently inhibits prolactin
release from the pituitary (Ben-Jonathon et al. 1989).
Plasma corticosterone levels were not affected by NmU
(up to equivalent dose of 1.14 nmol i.c.v.) in this study. In
contrast, Ozaki et al. (2002) showed elevated plasma
corticosterone and ACTH following a higher dose of NmU
(3 nmol i.c.v.). The presence of NmU in the PVN may be
required for effects on corticosterone as Wren et al. (2002)
showed increased plasma corticosterone and ACTH levels
following direct injection of a low dose of NmU
(0.3 nmol) to the PVN. If this were true, the relatively
low doses of NmU used in the present study may not be
sufficient to affect output from the PVN. Aside from the
lack of effect on corticosterone, evidence described here
and in the literature suggest that centrally administered
NmU affects HPA function, and other neuroendocrine
systems, via its actions on hypothalamic output systems.
Given that hypothalamo-pituitary output is influenced
by DA, and receives significant input from limbic systems
and various neurotransmitter systems, effects of NmU on
the DA and 5-HT systems were investigated. The ratios of
DA and 5-HT to their metabolites were measured in a
range of brain areas. Using this technique, altered 5-HT
and DA neurotransmission had previously been detected
following i.c.v. administration of neuropeptides. For
example, striatal and hypothalamic 5-HT metabolism are
altered by orexin-B (Jones et al. 2001). NmU significantly
elevated 5-HT levels in the frontal cortex and hypothal-
amus, with both increased levels of 5-HT and decreased
levels of its metabolites in the hypothalamus and hippo-
campus, suggesting decreased 5-HT utilisation. The
physiological significance of this effect requires further
investigation, although a hypothalamic role for NmU is
further implicated. The localisation of NmU-ir by in the
substantia nigra and nucleus accumbens (Domin et al.
1987), together with inhibition of prolactin release from
the pituitary, suggests a role for NmU in DA regulation.
However, NmU did not affect the ratio of DA to its
metabolites in any areas tested, suggesting an alternative
mechanism for prolactin regulation by NmU. More
sensitive and anatomically discrete methods of measure-
ment, e.g. microdialysis, will be of use in fully under-
standing the interactions between NmU and neurotrans-
mitter systems, including the 5-HT system, in the brain.
Finally, to define anatomical substrates involved in the
central actions of NmU, we measured FLI in the rat brain
as a marker of neuronal activation in pre-defined brain
regions. High levels of FLI in the nucleus accumbens and
frontal cortex are consistent with the localisation of
NMU2R mRNA in these regions and, together with
effects on the 5-HT system, may indicate roles for NmU in
sensory motor gating, arousal, attention and cognitive
function. In agreement with Ivanov et al. (2002), high
levels of FLI were observed in the central amygdala, an
area that is associated with emotional learning and
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memory. Interestingly, the amygdala is the only area of rat
brain expressing both NMU1R and NMU2R mRNA. A
role for NmU in fear conditioning is worthy of further
investigation. Fos expression in the central amygdala is
also consistent with the effects of NmU on HPA function.
The central nucleus of the amygdala contains CRH
neurons which play a role in stress-induced ACTH and
corticosterone release (Herman et al. 2003). Therefore,
activation of the central nucleus of the amygdala may
contribute towards the reported NmU effects on stress
hormones.
Given the high levels of FLI in the frontal cortex and
accumbens, and the stimulant-like effect of NmU on
behaviours, effects on PPI (measured as %PPI) of an
acoustic startle stimuli were determined. However, NmU
did not influence the amplitude of the startle response or %
PPI. In retrospect, this is consistent with lack of changes to
DA neurotransmission in any brain areas tested.
The lack of increased FLI in the hypothalamus is
surprising at first glance and contradicts reports by others
who showed FLI in the PVN, arcuate nucleus, supraoptic
nucleus, lateral hypothalamic area and dorsomedial nu-
cleus (Ozaki et al. 2002; Ivanov et al. 2002). This
discrepancy may be explained by the discrete localisation
of FLI in specific nuclei, the examination of which was
beyond the scope of this study. To gain a further insight
into brain areas activated by NmU, a more detailed
analysis of specific areas of interest, for example the
hypothalamus, should be undertaken. Additionally, future
studies should utilise alternative techniques to map
neuronal substrates for effects of NmU, for example,
pharmacological magnetic resonance imaging.
In summary, this series of studies confirms and extends
evidence for multiple roles for NmU and its receptors in
the brain. We have shown a widespread distribution of
NMU1R and NMU2R mRNA, showing that NmU exerts
central effects through NMU2R, and possibly NMU1R. To
extend the current understanding of centrally mediated
effects of NmU, we showed effects of i.c.v.-administered
NmU on 5-HT transmission in the hypothalamus; Fos
expression in the frontal cortex, nucleus accumbens and
amygdala; and plasma prolactin levels. These data are in
agreement with a role for NmU in regulating hypothalamic
output (Wren et al. 2002), but also suggest more diverse
roles for NmU. In future studies, selective tool compounds
acting at NmU receptors will help to determine roles for
NMU1R and NMU2R in the pharmacological actions of
NmU.
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